RxDoctor Payments Data

Kathryn Estopinal

Acute Care · Nashville, TNNPI 1194275560

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by Johnson & Johnson at 45.1% of the total. 2025 is the largest year on record at $20,359, more than ten times the $106 reported in 2021. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,345in general payments, 2019–2025

Across 259 payments — averaging $97.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Merck$8K
  • AstraZeneca$792
  • Regeneron Healthcare Solutions, Inc.$539
  • Gilead$516
  • Janssen Scientific Affairs, LLC$426
  • plus $4K from 46 others

What the payments were for

  • Speaking & faculty fees$14,13056%
  • Travel & lodging$3,41013%
  • Food & beverage$7,80531%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,345 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,897
Medicare patients
19
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide23$315,260
EliquisApixaban14$9,267
Olanzapine38$807
Ondansetron OdtOndansetron18$716
Oxycodone Hcl36$537
Levothyroxine Sodium37$219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$202
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$134
Prednisone23$106
Amlodipine Besylate13$99
Ciprofloxacin Hcl14$73
Potassium Chloride11$52
Furosemide14$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$126$315,26023 claims
PfizerEliquis$203$9,26714 claims
Lilly USA, LLCOlanzapine$26$80738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →